comparemela.com

Latest Breaking News On - Sutro biopharma - Page 1 : comparemela.com

Coping with a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO)

Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently .

Sutro-biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Buy" by Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have updated their coverage on the […]

United-states
America
Sutro-biopharma
Parkman-healthcare-partners
Sutro-biopharma-inc
Sutro-biopharma-company-profile
Nasdaq
Vanguard-group-inc
Acadian-asset-management
Get-free-report
Capital-partners
Capital-management

Sutro Biopharma's (STRO) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research note released on Tuesday, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2024 earnings at ($0.99) EPS, Q3 2024 earnings at ($1.01) EPS, Q4 […]

United-states
America
Piper-sandler
Sutro-biopharma
Vontobel-holding-ltd
Nasdaq
Exchange-traded-concepts
Sutro-biopharma-inc
Sutro-biopharma-company-profile
Acadian-asset-management
Panagora-asset-management-inc
Free-report

Oppenheimer Reaffirms "Outperform" Rating for Sutro Biopharma (NASDAQ:STRO)

Oppenheimer Reaffirms "Outperform" Rating for Sutro Biopharma (NASDAQ:STRO)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Piper-sandler
Sutro-biopharma
Acadian-asset-management
Sutro-biopharma-inc
Parkman-healthcare-partners
Vanguard-group-inc
Get-free-report
Capital-partners
Capital-management
Asset-management

Sutro Biopharma's (STRO) Outperform Rating Reaffirmed at Oppenheimer

Oppenheimer restated their outperform rating on shares of Sutro Biopharma (NASDAQ:STRO – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the stock. STRO has been the topic of a number of other reports. Piper Sandler reaffirmed an overweight rating and […]

United-states
America
Piper-sandler
Sutro-biopharma
Vanguard-group-inc
Sutro-biopharma-company-profile
Acadian-asset-management
Sutro-biopharma-inc
Parkman-healthcare-partners
Free-report
Truist-financial
Get-free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.